The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. Not surprising, SurveyMonkey (SVMK) was the week's top performer,...read more
Gritstone Oncology, a biotech developing personalized and off-the-shelf cancer immunotherapies, raised $100 million by offering 6.7 million shares at $15, the high end of the range of $13 to $15. The company had originally planned to sell 6.1 million shares....read more
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and...read more
Gritstone Oncology, a preclinical biotech developing a therapy that enhances checkpoint immuno-oncology drugs, announced terms for its IPO on Monday.
The Emeryville, CA-based company plans to raise $85 million by offering 6.1 million shares at a price range...read more
US IPO Weekly Recap: 12 IPOs wrap up active third quarter as SurveyMonkey pops 34%
The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. Not surprising, SurveyMonkey (SVMK) was the week's top performer,...read more
Gritstone Oncology prices upsized IPO at $15, the high end of the range
Gritstone Oncology, a biotech developing personalized and off-the-shelf cancer immunotherapies, raised $100 million by offering 6.7 million shares at $15, the high end of the range of $13 to $15. The company had originally planned to sell 6.1 million shares....read more
US IPO Week Ahead: 13 IPOs close out 3rd quarter with biotechs, China and SurveyMonkey
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and...read more
Cancer immunotherapy biotech Gritstone Oncology sets terms for $85 million IPO
Gritstone Oncology, a preclinical biotech developing a therapy that enhances checkpoint immuno-oncology drugs, announced terms for its IPO on Monday. The Emeryville, CA-based company plans to raise $85 million by offering 6.1 million shares at a price range...read more